Reference is made to the announcement by Ensurge Micropower ASA ("Ensurge" or the "Company") on 8 August 2025 regarding the Extraordinary General Meeting held on the same day, where all proposals on the agenda were approved by the shareholders. The Extraordinary General Meeting approved the issuance of independent subscription rights in the Company to each of Alexander Munch Thore, Chair of the Board (13,000,000 subscription rights) and Thomas Ramm, Board member (8,000,000 subscription rights). All issued s ...

Core Points - Galapagos NV has created 925,000 subscription rights under a new plan aimed at senior management compensation [1][2] - The subscription rights have an exercise term of eight years and an exercise price of €25.64, with restrictions on early exercise [2] - The total share capital of Galapagos is €356,444,938.61, with 65,897,071 voting rights currently outstanding [3] Summary by Sections Subscription Rights Plan - The Board of Directors approved "Subscription Right Plan 2025 (A)" for personnel, creating 925,000 subscription rights [1] - Each subscription right allows the holder to subscribe to one new share of Galapagos [2] - The rights cannot be exercised before the third anniversary of issuance [2] Financial Overview - Galapagos' total share capital is €356,444,938.61, with 65,897,071 voting rights [3] - There are 11,866,245 subscription rights from various employee plans, excluding the new rights created [3] - Gilead Therapeutics holds a subscription right to maintain a 29.9% shareholding after exercise [3] Company Profile - Galapagos is a biotechnology company focused on addressing high unmet medical needs through innovative science and technology [4] - The company operates in Europe, the U.S., and Asia, aiming to improve patient outcomes and quality of life [4] - Galapagos is committed to delivering best-in-class medicines and has a decentralized cell therapy manufacturing platform [4]

Core Points - The Nomination Committee was elected at the AGM on 14 May 2024, consisting of Robert N. Keith (Chair), Rune Sundvall, and Christian Schlytter-Henrichsen [1] - Two members of the Nomination Committee resigned, leaving only Robert N. Keith, which is below the minimum required by the Company's Articles of Association [2] - The Chair has been in contact with the Company's management and major shareholders to define the desired profile of Board members [3] Board Composition - The current Board consists of Terje Rogne (Chair), Morten Opstad, and Nina Riibe, all of whom are up for re-election at the upcoming AGM [5][6] - The current Board members are willing to continue for a new two-year term, and the Nomination Committee proposes their re-election [6][7] Board Remuneration - The remuneration for Board members for the period from the 2025 AGM to the 2026 AGM is proposed to be NOK 300,000 per member, payable quarterly [10] - The same level of cash remuneration is proposed for the next term, with the first payment due on 31 August 2025 [10] Subscription Rights - The Nomination Committee proposes grants of incentive subscription rights to Terje Rogne (16,000,000 rights) and Morten Opstad (5,000,000 rights) [11][13] - The vesting schedule for these subscription rights is proposed to be 10% after one year, 20% after two years, and 70% after three years [12][17] Nomination Committee Remuneration - The Chair of the Nomination Committee proposes that no remuneration is paid to the resigned members for their services from the 2024 AGM until their resignations [23] - Robert N. Keith waives his right to a remuneration fee [23] Nomination Committee Election - Robert N. Keith is proposed to be re-elected as Chair of the Nomination Committee, with Andreas Ellingsen and Fredrik Munck as new members for a one-year term [24]